A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced hepatocellular carcinoma (HCC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial. 2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination therapy or monotherapy in the treatment of HCC compared to the combinat

Trial Details

NCT ID
NCT06530251
Phase
PHASE1 / PHASE2
Sponsor
Akeso
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • AK112
  • Cadonilimab
  • AK127
  • AK130
  • Sintilimab Injection
  • Bevacizumab biosimilar
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Be able and willing to provide written informed consent.
  • Have a life expectancy of at least 3 months.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • HCC confirmed by histology/cytology or confirmed by the American Society for the Study of Hepatology (AASLD) clinical diagnostic criteria for hepat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →